{
  "_metadata": {
    "version": "2.1",
    "ticker": "EWTX",
    "asset_name": "EDG-15400",
    "extraction_date": "2026-02-11",
    "source_id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf"
  },
  "asset": {
    "name": "EDG-15400",
    "company": "Edgewise Therapeutics",
    "ticker": "EWTX",
    "stage": "Phase 1",
    "modality": "Small molecule",
    "ownership": "Wholly-owned",
    "one_liner": "EDG-15400 is a small molecule cardiac sarcomere modulator with an undisclosed target intended for future development in heart failure with preserved ejection fraction (HFpEF)."
  },
  "target": {
    "name": "Undisclosed cardiac sarcomeric target",
    "full_name": "Undisclosed cardiac sarcomeric target",
    "class": "Cardiac sarcomere protein",
    "pathway": "Cardiac sarcomere function",
    "biology": {
      "simple_explanation": "The cardiac sarcomere is the basic contractile unit of heart muscle. EDG-15400 targets an undisclosed protein within the sarcomere to potentially improve cardiac function in heart failure with preserved ejection fraction.",
      "pathway_detail": null,
      "downstream_effects": []
    },
    "why_good_target": {
      "clinical_validation": null,
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": null
      },
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 5,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "Cardiac sarcomere modulator",
    "how_it_works": "Undisclosed mechanism targeting cardiac sarcomeric proteins",
    "differentiation": "Part of Edgewise's muscle-focused platform with expertise in sarcomere biology",
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": 5,
      "verified": false
    }
  },
  "regulatory": {
    "designations": [],
    "planned_pathway": {
      "type": null,
      "surrogate_endpoint": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    }
  },
  "partnership": {
    "_note": "Wholly-owned; no partnership",
    "partner": null,
    "territory": null,
    "economics": null
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": null,
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": null,
        "rationale": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": null,
      "by_dose": null
    },
    "pk_summary": "No pharmacokinetic data available"
  },
  "indications": {
    "lead": {
      "name": "Heart Failure with Preserved Ejection Fraction (HFpEF)",
      "patient_population": "Patients with HFpEF",
      "current_penetration": null,
      "rationale": "Part of Edgewise's cardiovascular pipeline expansion",
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 4,
        "verified": false
      }
    },
    "expansion": []
  },
  "clinical_data": {
    "trials": [
      {
        "name": "Phase 1 study in healthy adults",
        "nct_id": null,
        "phase": "Phase 1",
        "status": "Ongoing",
        "design": "Phase 1 study in healthy adults",
        "enrollment": "Healthy adults",
        "arms": [],
        "primary_endpoint": {
          "name": null,
          "definition": null,
          "result": null,
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": null,
            "verified": false
          }
        },
        "secondary_endpoints": [],
        "biomarkers": [],
        "safety": {
          "summary": null,
          "key_aes": null,
          "discontinuations": null,
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 4,
          "verified": false
        }
      }
    ]
  },
  "differentiation_claims": [],
  "competitive_landscape": {
    "competitors": [],
    "_note": "No competitive landscape information provided for HFpEF indication"
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": null,
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "tam": null,
    "patient_population": null,
    "unmet_need": "Heart failure with preserved ejection fraction represents a significant unmet medical need",
    "pricing_benchmark": null,
    "peak_sales_estimate": null,
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": null,
      "verified": false
    }
  },
  "catalysts": [
    {
      "event": "Phase 1 EDG-15400 healthy volunteer data",
      "timing": "H1 2026",
      "importance": "medium",
      "what_to_watch": "Safety and tolerability profile in healthy volunteers",
      "bull_scenario": "Clean safety profile enabling progression to Phase 2 in HFpEF",
      "bear_scenario": "Safety concerns or unfavorable profile delaying development"
    },
    {
      "event": "EDG-15400 Phase 2 initiation in HFpEF",
      "timing": "H2 2026",
      "importance": "high",
      "what_to_watch": "Trial design and patient population selection",
      "bull_scenario": "Successful initiation of Phase 2 study with appropriate endpoints",
      "bear_scenario": "Delays in Phase 2 initiation or challenging trial design"
    },
    {
      "event": "EDG-15400 Phase 2 data in HFpEF",
      "timing": "H1 2027",
      "importance": "critical",
      "what_to_watch": "Efficacy signals and safety profile in HFpEF patients",
      "bull_scenario": "Positive efficacy signals supporting advancement to Phase 3",
      "bear_scenario": "Lack of efficacy or safety concerns halting development"
    }
  ],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Very early stage with limited disclosed information about target and mechanism",
      "HFpEF is a challenging indication with high failure rates",
      "Competition from established cardiovascular companies"
    ],
    "bull_case": [
      {
        "thesis": "Edgewise's muscle biology expertise could translate to novel HFpEF approach",
        "evidence": "Company's successful development of sarcomere modulators in other indications",
        "confidence": "low"
      }
    ],
    "bear_case": [
      {
        "thesis": "Very early stage asset with undisclosed mechanism in competitive HFpEF space",
        "evidence": "No clinical data available and target/mechanism undisclosed",
        "confidence": "medium"
      }
    ],
    "key_debates": [
      {
        "question": "Can Edgewise's sarcomere expertise translate to HFpEF success?",
        "bull_view": "Muscle biology platform provides unique insights for cardiac applications",
        "bear_view": "HFpEF is fundamentally different from muscular dystrophies",
        "what_resolves_it": "Phase 1 safety data and Phase 2 efficacy signals"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "low",
    "missing_critical_fields": [
      "target identity",
      "mechanism of action details",
      "clinical trial design",
      "pharmacology data",
      "competitive landscape",
      "market opportunity sizing"
    ],
    "recommended_supplementary_sources": [
      "Edgewise SEC filings for more program details",
      "Scientific presentations on EDG-15400",
      "ClinicalTrials.gov for trial protocols"
    ]
  }
}